Evidence map›Paper›PMID 33340275›Full record

ReviewPhysiological reports2021

Altitude and COVID-19: Friend or foe? A narrative review.

Grégoire P Millet, Tadej Debevec, Franck Brocherie, Martin Burtscher, Johannes Burtscher

Open access · goldAbstract readReview
In one paragraph

Review in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 68 citations in OpenAlex.

  1. Altitude and case fatality rate from COVID-19 during the pandemic in Peru, 2020-2022.Revista peruana de medicina experimental y salud publica · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Understanding Acute Respiratory Distress Syndrome in High-Altitude Environments: A Comprehensive Review of Diagnosis and Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Health Benefits of Residence at Moderate Altitude Do Not Reduce COVID-19 Mortality.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. SARS-CoV-2 Viral Load Analysis at Low and High Altitude: A Case Study from Ecuador.International journal of environmental research and public health · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Grégoire P MilletInstitute of sport Sciences, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0001-8081-4423
Tadej DebevecFaculty of Sport, University of Ljubljana, Ljubljana, Slovenia.ORCID https://orcid.org/0000-0001-7053-3978
Franck BrocherieFrench Institute of Sport (INSEP), Paris, France.ORCID https://orcid.org/0000-0002-0808-7986
Martin BurtscherUniversity of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-5232-3632
Johannes BurtscherInstitute of sport Sciences, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-2889-0151
University of Lausanne · CHInstitut National du Sport, de l'Expertise et de la Performance · FRUniversität Innsbruck · ATUniversity of Ljubljana · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent reports suggest that high-altitude residence may be beneficial in the novel coronavirus disease (COVID-19) implicating that traveling to high places or using hypoxic conditioning thus could be favorable as well. Physiological high-altitude characteristics and symptoms of altitude illnesses furthermore seem similar to several pathologies associated with COVID-19. As a consequence, high altitude and hypoxia research and related clinical practices are discussed for potential applications in COVID-19 prevention and treatment. We summarize the currently available evidence on the relationship between altitude/hypoxia conditions and COVID-19 epidemiology and pathophysiology. The potential for treatment strategies used for altitude illnesses is evaluated. Symptomatic overlaps in the pathophysiology of COVID-19 induced ARDS and high altitude illnesses (i.e., hypoxemia, dyspnea…) have been reported but are also common to other pathologies (i.e., heart failure, pulmonary embolism, COPD…). Most treatments of altitude illnesses have limited value and may even be detrimental in COVID-19. Some may be efficient, potentially the corticosteroid dexamethasone. Physiological adaptations to altitude/hypoxia can exert diverse effects, depending on the constitution of the target individual and the hypoxic dose. In healthy individuals, they may optimize oxygen supply and increase mitochondrial, antioxidant, and immune system function. It is highly debated if these physiological responses to hypoxia overlap in many instances with SARS-CoV-2 infection and may exert preventive effects under very specific conditions. The temporal overlap of SARS-CoV-2 infection and exposure to altitude/hypoxia may be detrimental. No evidence-based knowledge is presently available on whether and how altitude/hypoxia may prevent, treat or aggravate COVID-19. The reported lower incidence and mortality of COVID-19 in high-altitude places remain to be confirmed. High-altitude illnesses and COVID-19 pathologies exhibit clear pathophysiological differences. While potentially effective as a prophylactic measure, altitude/hypoxia is likely associated with elevated risks for patients with COVID-19. Altogether, the different points discussed in this review are of possibly some relevance for individuals who aim to reach high-altitude areas. However, due to the ever-changing state of understanding of COVID-19, all points discussed in this review may be out of date at the time of its publication.

Indexed as

AcclimatizationAltitudeAltitude SicknessAnimalsCOVID-19HumansPrevalencePrognosisProtective FactorsRisk AssessmentRisk Factorscoronavirushypoxemiahypoxiaimmunitymitochondriapandemic

Identifiers

PMID33340275
PMCPMC7749581
OpenAlexW3116842426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.